Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2008

View Archived Issues

Stanford University identifies two potential drug targets to treat malaria

Transcutaneous immunization effective in protecting against enterohemorrhagic E. coli infection

New antiinfective agents described in recent GSK patents

Activation of the unfolded protein response central in the pathogenesis of Charcot-Marie-Tooth 1B

Trophos receives grant to evaluate TRO-19622 in Parkinson's disease

Cogentus appoints Scientific Steering Committee for CGT-2168 phase III clinical program

University of Adelaide awarded AUD 2 million grant for five-year hepatitis C project

Toyama Chemical initiates phase II trial of T-5224 for rheumatoid arthritis

Takeda profiles Q3 developments

Risperidone long-acting injection delays relapse in bipolar disorder

Studies show aripiprazole efficacy in pediatric psychological disorders

Recent patents impart novel therapeutic agents for respiratory disorders

New antiinfective agents reported in recent patents

OctoPlus and Biolex commence phase IIa Locteron study in hepatitis C

MGCD-0103 receives orphan drug designation for acute myelogenous leukemia

Merck KGaA and Novo Nordisk disclose new diabetes compounds in recent patent literature

Pharmacopeia selects novel chemokine receptor antagonist for development

TopoTarget clarifies collaboration with Leo Pharma

Sosei commences AD-923 phase III studies in Europe

Promising interim results reported from phase III Zadaxin trial in hepatitis C

Symbollon Pharmaceuticals completes phase III trial of IoGen for fibrocystic breast disease

Solstice Neurosciences responds to FDA early communication regarding Myobloc for cervical dystonia

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...